Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback